Form 4: Predictive Oncology Director Matthew Hawryluk Reports Stock Transactions
SEC Form 4 Filing
Director Matthew Hawryluk of Predictive Oncology Inc. reports acquiring and disposing of common stock on April 5, 2024.
Summary
- On April 5, 2024, Matthew Hawryluk, a director of Predictive Oncology Inc., engaged in transactions involving the company's common stock.
- Hawryluk acquired 2,368 shares of common stock at a price of $0.
- Simultaneously, Hawryluk disposed of 9,488 shares of common stock.
- Following these transactions, the reported beneficial ownership of common stock is not explicitly stated in the provided document.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, like directors, who trade in their company's stock. It provides transparency to the market regarding insider activity.
Stakeholder Impact
- Shareholders may be interested in this filing as it provides information on insider trading activity, which can sometimes influence stock prices.
Key Dates
| Date | Description |
|---|---|
| 04/05/2024 | Date of stock acquisition and disposition. |
| 04/12/2024 | Date of signature for the report. |
Keywords
Predictive Oncology Inc., POAI, Form 4, insider trading, Matthew Hawryluk, stock transaction, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.